Compare GKOS & RMBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | RMBS |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.5B |
| IPO Year | 2015 | 1997 |
| Metric | GKOS | RMBS |
|---|---|---|
| Price | $180.54 | $89.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $199.31 | $140.57 |
| AVG Volume (30 Days) | 979.8K | ★ 1.7M |
| Earning Date | 10-28-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.88 |
| EPS | N/A | ★ 1.84 |
| Revenue | $507,442,000.00 | ★ $707,630,000.00 |
| Revenue This Year | $36.30 | $18.48 |
| Revenue Next Year | $23.25 | $20.50 |
| P/E Ratio | ★ N/A | $48.92 |
| Revenue Growth | ★ 32.33 | 27.13 |
| 52 Week Low | $80.91 | $77.89 |
| 52 Week High | $191.62 | $174.10 |
| Indicator | GKOS | RMBS |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 43.74 |
| Support Level | $175.04 | $81.38 |
| Resistance Level | $184.68 | $104.44 |
| Average True Range (ATR) | 6.45 | 5.25 |
| MACD | 1.90 | -1.25 |
| Stochastic Oscillator | 80.18 | 23.79 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.